Effects of esmolol on patients with left ventricular dysfunction.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Severe left ventricular dysfunction poses significant clinical challenges.
• Beta-adrenergic blockade is a key therapeutic strategy in cardiovascular disease.

Purpose of the Study:

• To evaluate the hemodynamic effects of esmolol, an ultrashort-acting beta-receptor blocker, in patients with severe left ventricular dysfunction.
• To determine the dose-response relationship of esmolol in this patient population.

Main Methods:

• Simultaneous hemodynamic and radionuclide angiographic measurements were performed.
• Incremental doses of esmolol (2-16 mg/min) were administered to 10 patients.
• Measurements included heart rate, systolic aortic pressure, ejection fractions, and cardiac output.

Main Results:

• A dose of 4 mg/min achieved beta-blockade, decreasing heart rate and systolic aortic pressure.
• Maximal doses reduced heart rate and depressed biventricular function (left and right ventricular ejection fractions decreased).
• Hemodynamic abnormalities, including increased ventricular volumes and pulmonary artery wedge pressure, were observed at higher doses but reversed post-infusion.

Conclusions:

• Esmolol can be safely administered to patients with severe left ventricular dysfunction.
• Therapeutic beta-adrenergic blockade is typically achieved at low esmolol doses without significant adverse hemodynamic effects.
• Higher esmolol doses may lead to biventricular dysfunction, necessitating careful dose titration.